Achilles Therapeutics company info

What does Achilles Therapeutics do?
Achilles Therapeutics PLC ADR (NASDAQ:ACHL) is a biotechnology firm dedicated to developing next-generation, patient-specific therapies that target cancer. The company's innovative approach focuses on harnessing the power of T-cell therapies to treat solid tumors, aiming to create treatments that are more effective and personalized. Achilles Therapeutics is at the forefront of identifying and utilizing clonal neoantigens, which are unique to each tumor, to activate the immune system specifically against cancer cells, leaving healthy cells untouched. Their pipeline includes projects for various types of cancer, with objectives aimed at significantly improving patient outcomes. Through cutting-edge research and clinical trials, Achilles Therapeutics is committed to advancing the fight against cancer with personalized immunotherapies.
Achilles Therapeutics  company media
Company Snapshot

Is Achilles Therapeutics a public or private company?

key
Ownership
Public

How many people does Achilles Therapeutics employ?

people
Employees
210

What sector is Achilles Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Achilles Therapeutics ?

location pin
Head Office
London, United Kingdom

What year was Achilles Therapeutics founded?

founded flag
Year Founded
2016
What does Achilles Therapeutics specialise in?
/Cancer Therapies /T-cell Therapies /Clonal Neoantigen /Immuno-Oncology Research /Genomic Medicine /Personalized Healthcare

What are the products and/or services of Achilles Therapeutics ?

Overview of Achilles Therapeutics offerings
Clonal Neoantigen TCR T cell therapies target and destroy tumor cells by focusing on unique neoantigens from individual cancer mutations.
Personalized cancer vaccines aim to prime the immune system against specific tumor neoantigens to prevent cancer recurrence.
Biomarker discovery platforms for identifying unique cancer neoantigens ensure targeted and personalized therapeutic approaches.
Advanced manufacturing processes for T-cell therapies streamline production, ensuring rapid delivery of personalized treatments to patients.
Collaborations with biotech and pharmaceutical companies to expand research, development, and distribution capacities for next-generation cancer therapies.
Patient access programs designed to make innovative treatments more accessible, supporting those with unmet medical needs in oncology.

Who is in the executive team of Achilles Therapeutics ?

Achilles Therapeutics leadership team
  • Dr. Iraj  Ali Ph.D.
    Dr. Iraj Ali Ph.D.
    CEO & Director
  • Dr. Karl Stuart Peggs M.D.
    Dr. Karl Stuart Peggs M.D.
    Founder & Chief Medical Officer
  • Dr. Sergio A. Quezada Ph.D.
    Dr. Sergio A. Quezada Ph.D.
    Founder & Chief Scientific Officer
  • Mr. Robert  Coutts
    Mr. Robert Coutts
    Chief Financial Officer
  • Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.
    Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.
    Founder
  • Dr. Charles  Swanton FMEDSCI, M.D., Ph.D.
    Dr. Charles Swanton FMEDSCI, M.D., Ph.D.
    Founder
  • Mr. Lee M. Stern
    Mr. Lee M. Stern
    Vice President of Investor Relations & External Communications
  • Mr. Daniel Carey Cazel Hood
    Mr. Daniel Carey Cazel Hood
    General Counsel & Company Secretary